News
PRRUF
0.017
NaN%
--
Immutep announces data from its Phase I study of IMP761
TipRanks · 11/09 00:25
Immutep Reports Positive Phase I Data for Autoimmune Candidate IMP761
TipRanks · 11/08 22:13
Immutep to Present Efti Trial Data at Two Oncology Congresses
TipRanks · 11/04 22:21
Immutep Refocuses Efti Development, Elevates IMP761 as Cash Runway Extends to 2028
TipRanks · 10/28 21:37
Immutep Sets Date and Agenda for 2026 Annual General Meeting
TipRanks · 10/27 02:57
Immutep Files Updated Corporate Governance Disclosures for FY2026
TipRanks · 10/27 02:47
Immutep Sets Out Governance and Market Footing in 2026 Annual Report
TipRanks · 10/27 02:37
Immutep Files 2026 Form 20-F, Confirms Accelerated Filer Status
TipRanks · 10/25 21:55
Immutep presents HRQoL data from EFTISARC-NEO trial
TipRanks · 10/23 13:01
Immutep’s Sarcoma Trial Shows Stable Quality of Life and Post-Surgery Gains
TipRanks · 10/23 06:25
Immutep Earns Buy Rating on First-in-Class LAG-3 Agonist IMP761, Strong Phase 1 Data, and Cash Runway Into 2028
TipRanks · 10/22 05:35
Immutep’s First-in-Class LAG-3 Agonist IMP761 Secures Late-Breaking Slot at ACR 2026
TipRanks · 10/19 07:13
Immutep, Monash University secure further ARC linkage projects
TipRanks · 10/14 12:15
Immutep, Monash Win New ARC Grant to Advance LAG-3 Research
TipRanks · 10/13 22:32
Immutep Restores Nasdaq Bid Price Compliance with ADS Ratio Change
TipRanks · 10/13 01:07
Immutep Moves to Restore ASX Audit Committee Compliance After Director Exit
TipRanks · 10/09 06:14
Immutep Details Equity Interests of Departing Director Pete Meyers
TipRanks · 10/04 23:02
Immutep Announces Board Resignation and Search for New Non-Executive Director
TipRanks · 10/04 22:48
Immutep Director Increases Shareholding Through Performance Rights Exercise
TipRanks · 09/30 22:55
Immutep Applies to Quote New Ordinary Shares on ASX
TipRanks · 09/30 22:55
More
Webull provides a variety of real-time PRRUF stock news. You can receive the latest news about Immutep Ltd through multiple platforms. This information may help you make smarter investment decisions.
About PRRUF
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.